肿瘤细胞治疗研究
FRONTIER PAPERS
Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.
胶质母细胞瘤（GB）仍是治疗抵抗性最强的实体瘤之一，其特征是显著的代谢可塑性、瘤内异质性和高度免疫抑制的微环境。
CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials.
胶质母细胞瘤（GBM）是一种侵袭性原发性脑肿瘤，预后不良，有效治疗方案很少。
Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.
自然杀伤（NK）细胞是固有免疫的关键组成部分，无需预先致敏即具有清除肿瘤细胞的能力。
Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st
检索获得 324 条记录；去除 103 条重复记录；筛选 221 篇标题和摘要；审阅 180 篇全文；由两名独立评价者提取 34 项研究。
Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.
多形性胶质母细胞瘤（GBM）是最常见的原发性恶性脑肿瘤类型，总生存率极低。
Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D
我们的结果表明，将携带活化 NKAR 受体的 NK 细胞与双特异性 NKAB 抗体联合使用，可实现灵活靶向，从而增强肿瘤抗原特异性细胞毒性并防止免疫逃逸。
CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
CAR-T 细胞（CAR-T 细胞）是经过工程化改造的细胞，表达针对特定肿瘤抗原（TA）的嵌合抗原受体（CAR），从而能够识别并清除癌细胞。
Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment.
例如，同时给药时肿瘤缩小百分比为 7.1%，而序贯给药时为 6.7%。
Clinical progress in the development of CAR T cells to treat malignant glioma.
在研 CAR-T 细胞疗法的快速演进预示着胶质瘤治疗未来的巨大潜力。
Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.
我们的结果表明，7 19 CAR-T 可能成为胶质母细胞瘤和胰腺癌的一种治疗选择。
MEMBER ACCOUNT
登录成功会直接打开下一页。
